Page last updated: 2024-12-08

((4-bromobenzyl)oxy)acetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## ((4-bromobenzyl)oxy)acetic acid: A Closer Look

**((4-bromobenzyl)oxy)acetic acid** is a synthetic organic compound. It's composed of a benzyl group (a benzene ring attached to a CH2 group), a bromine atom attached to the benzene ring at the 4-position, and an oxy acetic acid group.

**Here's a breakdown of the structure and nomenclature:**

* **(4-bromobenzyl)**: This part indicates the benzyl group with a bromine atom at the 4th position on the benzene ring (referring to the position relative to the CH2 group).
* **(oxy)**: This signifies that the benzyl group is connected to the rest of the molecule via an oxygen atom.
* **acetic acid**: This indicates the presence of a CH2COOH group (acetic acid).

**Importance in Research:**

While ((4-bromobenzyl)oxy)acetic acid itself might not be widely studied, compounds with similar structures are often used in research, particularly in:

* **Pharmaceutical Chemistry:**
* **Drug discovery:** Analogs of this compound might be explored for their potential as drug candidates, particularly for targeting specific enzymes or receptors involved in various diseases.
* **Drug delivery:** This type of structure could potentially be modified to create drug delivery systems that target specific tissues or organs.
* **Materials Science:**
* **Polymer synthesis:** The compound could serve as a building block for synthesizing novel polymers with specific properties, such as conductivity or biocompatibility.
* **Surface modification:** The molecule might be used to functionalize surfaces with specific properties for applications in electronics, catalysis, or biomaterials.

**Key points to consider:**

* **Specific research:** It's important to note that the exact importance of ((4-bromobenzyl)oxy)acetic acid depends on the specific research being conducted.
* **Analogs:** Research efforts often focus on analogs of this compound, where the bromine atom or the acetic acid group might be replaced with other functional groups. These modifications can influence the compound's properties and biological activity.

**To understand the specific importance of this compound in a particular research context, it's crucial to consult the relevant scientific literature or publications.**

**In summary, ((4-bromobenzyl)oxy)acetic acid itself might not be a highly researched compound. However, its structural components are frequently found in molecules with diverse applications in pharmaceutical and materials science research.**

((4-bromobenzyl)oxy)acetic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133921
CHEMBL ID9256
SCHEMBL ID1760266
MeSH IDM0177422

Synonyms (27)

Synonym
82499-60-3
((4-bromobenzyl)oxy)acetic acid
acetic acid, ((4-bromophenyl)methoxy)-
IDI1_014213
SR-01000003498-2
MAYBRIDGE3_002826
bbaa
HMS1439A10
CHEMBL9256
2-[(4-bromophenyl)methoxy]acetic acid
2-[(4-bromobenzyl)oxy]acetic acid
AKOS015994501
CCG-43824
BP-10433
SS-3063
SCHEMBL1760266
DTXSID20231793
(4-bromo-benzyloxy)-acetic acid
2-((4-bromobenzyl)oxy)acetic acid
ZIEXYIQTFZVRBI-UHFFFAOYSA-N
mfcd04123920
SR-01000003498-1
sr-01000003498
(4-bromobenzyloxy)-acetic acid
BRD-K40409336-001-01-3
2-[(4-bromobenzyl)oxy]aceticacid
EN300-316249
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID22008Compound was evaluated, at a concentration of 10 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID22149Solubility ratio ([HbS+drug (5 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID22013Solubility ratio ([HbS+drug (20 mM)]/[HbS-drug]1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID22010Compound was evaluated, at a concentration of 40 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID19554Compound was evaluated, at a concentration of 10 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID22148Solubility ratio ([HbS+drug (40 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID21143Solubility of Deoxyhemoglobin S (dHbS) concentration after addition dithionite as control1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID21145Solubility of Haemoglobin S (HbS) concentration after addition of acid and dithionite1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID19558Compound was evaluated, at a concentration of 5 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID19555Compound was evaluated, at a concentration of 20 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID19557Compound was evaluated, at a concentration of 40 mM acid, for its ability to increase the solubility of sickle hemoglobin1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID22011Compound was evaluated, at a concentration of 5 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID22009Compound was evaluated, at a concentration of 20 mM acid, the solubility ratio is obtained by dividing the solubility of sickle hemoglobin (HbS) with the compound (grams per deciliter) by the solubility of the untreated sample (grams per deciliter)1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Design, synthesis, and testing of potential antisickling agents. 3. Ethacrynic acid.
AID22012Solubility ratio ([HbS+drug (10 mM)]/[HbS-drug])1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Design, synthesis, and testing of potential antisickling agents. 4. Structure-activity relationships of benzyloxy and phenoxy acids.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]